Form 4: Dyne Therapeutics Chief Medical Officer Sells Shares to Cover Tax Obligations and Under 10b5-1 Trading Plan

Sentiment:

SEC Form 4 Filing


Wildon Farwell, Chief Medical Officer of Dyne Therapeutics, sold shares to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Summary

  • Wildon Farwell, the Chief Medical Officer of Dyne Therapeutics, sold 8,364 shares of common stock on March 7, 2024, at a weighted average price of $25.8.
  • These shares were sold to satisfy tax withholding obligations related to the vesting of restricted stock units granted on March 2, 2021, and November 15, 2023.
  • Additionally, Farwell sold 1,557 shares on the same day at a weighted average price of $26.2 under a Rule 10b5-1 trading plan adopted on July 14, 2023.
  • Following these transactions, Farwell directly owns 153,175 shares of Dyne Therapeutics, which includes 128,010 unvested RSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions appear to be routine and related to tax obligations and a pre-planned trading strategy. There is no indication of a change in the insider's confidence in the company.

Industry Context

Sales by company insiders are common and can be for various reasons, including diversification, tax obligations, or pre-planned trading strategies. The use of a 10b5-1 trading plan suggests the insider is selling shares in a structured way to avoid accusations of insider trading.

Key Dates

DateDescription
2021-03-02Date of restricted stock unit grant related to tax obligation sales.
2023-07-14Date of adoption of Rule 10b5-1 trading plan.
2023-11-15Date of restricted stock unit grant related to tax obligation sales.
2024-03-07Date of share sales.
2024-03-11Date of Form 4 signature.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.